{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:15:38Z","timestamp":1792091738283,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2) and cluster of differentiation 3, in mCRPC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Patients who had measurable\/evaluable mCRPC after at least one novel androgen receptor\u2013targeted therapy or chemotherapy were eligible. Participants received subcutaneous JNJ-902 0.3, 1.0, 1.5, 3.0, or 6.0\u00a0mg once weekly (QW) or 2.0, 3.0, 4.0, or 6.0\u00a0mg biweekly (Q2W). Study objectives included assessment of safety, pharmacokinetics, immunogenicity, and preliminary efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-two participants were enrolled to receive at least one dose of JNJ-902 (QW; n\u2005=\u200538; Q2W; n\u2005=\u200544). Median duration of treatment was 1.91 (0.0-19.4) months across dosing groups. All participants experienced at least one treatment-emergent adverse event (TEAE) and 76 (92.7%) experienced treatment-related TEAEs. Fourteen participants (17.1%) experienced a TEAE that led to study discontinuation, of which 3 (3.7%) were related to JNJ-902. Dose-limiting toxicities were observed in 2 participants (2.4%). Five participants (15.2%) with measurable disease had a confirmed partial response and 10 participants (12.2%) had \u226550% decrease from baseline prostate-specific antigen levels. Clinical activity was not dose related and no clear exposure-response relationship was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, dose escalation was limited by emerging dose-limiting toxicities. Although a recommended phase II dose was not determined, findings indicate TMEFF2 to be a potential target in mCRPC that warrants further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae313","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:24:40Z","timestamp":1737386680000},"source":"Crossref","is-referenced-by-count":14,"title":["A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"first","affiliation":[{"name":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal , 28050 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Doger","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , 28040 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital , 08035\u00a0Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus , Haifa, 3109601 ,\u00a0","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarid","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center , Tel Aviv, 6423906 ,\u00a0","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J","family":"Eigl","sequence":"additional","affiliation":[{"name":"BC Cancer \u2013 Vancouver , Vancouver, BC V5Z 4E6 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Avadhani","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yao","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lin","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujian","family":"Wu","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pharavee","family":"Jaiprasart","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Loffredo","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monelle","family":"Tamegnon","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichun","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xie","sequence":"additional","affiliation":[{"name":"Janssen R&D , Raritan, NJ, 08869 ,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,\u00a0Princess Margaret Hospital , Toronto, ON M5G 2M9 ,","place":["Canada"]},{"name":"Department of Medicine,\u00a0University of Queensland , Brisbane, QLD 4072 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2025031509015507000_CIT0001","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"2025031509015507000_CIT0002","volume-title":"Cancer Stat Facts. Prostate Cancer.","author":"National Cancer Institute","year":"2023"},{"key":"2025031509015507000_CIT0003","first-page":"207","article-title":"KLK-targeted therapies for prostate cancer","volume":"25","author":"Hannu","year":"2014","journal-title":"Ejifcc"},{"key":"2025031509015507000_CIT0004","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"2025031509015507000_CIT0005","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/RRU.S360444","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res. Rep Urol"},{"key":"2025031509015507000_CIT0006","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"Network NCC","year":"2024"},{"key":"2025031509015507000_CIT0007","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/jco.2022.40.28_suppl.144","article-title":"Overall survival by race and ethnicity among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population","volume":"40","author":"Freedland","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025031509015507000_CIT0008","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025031509015507000_CIT0009","article-title":"TECVAYLI\u00ae (teclistamab-cqyv) prescribing information","volume-title":"Janssen Pharmaceuticals Inc. 2023","author":"Janssen Pharmaceuticals Inc","year":"2023"},{"key":"2025031509015507000_CIT0010","article-title":"TALVEY\u2122 (talquetamab-tgvs) prescribing information","volume-title":"Janssen Pharmaceuticals Inc","author":"Janssen Pharmaceuticals Inc","year":"2023"},{"key":"2025031509015507000_CIT0011","article-title":"BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use","volume-title":"Amgen Inc","author":"Amgen Inc","year":"2023"},{"key":"2025031509015507000_CIT0012","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41391-021-00381-w","article-title":"Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs","volume":"24","author":"Zorko","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025031509015507000_CIT0013","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1200\/jco.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025031509015507000_CIT0014","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/jco.2023.41.6_suppl.154","article-title":"Preliminary results from a phase 1\/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Stein","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025031509015507000_CIT0015","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","article-title":"Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells","volume":"41","author":"Liu","year":"2012","journal-title":"Int J Oncol"},{"key":"2025031509015507000_CIT0016","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13550-020-00723-0","article-title":"[(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study","volume":"10","author":"Hober\u00fcck","year":"2020","journal-title":"EJNMMI Res"},{"key":"2025031509015507000_CIT0017","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.921.3.8","article-title":"Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer","volume":"3","author":"Afar","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2025031509015507000_CIT0018","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ijc.1450","article-title":"TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence","volume":"94","author":"Glynne-Jones","year":"2001","journal-title":"Int J Cancer"},{"key":"2025031509015507000_CIT0019","first-page":"4907","article-title":"The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells","volume":"60","author":"Liang","year":"2000","journal-title":"Cancer Res"},{"key":"2025031509015507000_CIT0020","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers12123862","article-title":"TMEFF2: a transmembrane proteoglycan with multifaceted actions in cancer and disease","volume":"12","author":"Masood","year":"2020","journal-title":"Cancers."},{"key":"2025031509015507000_CIT0021","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbrc.2012.07.064","article-title":"Generation and characterization of Tmeff2 mutant mice","volume":"425","author":"Chen","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2025031509015507000_CIT0022","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1593\/tlo.08124","article-title":"Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells","volume":"1","author":"Zhao","year":"2008","journal-title":"Transl Oncol"},{"key":"2025031509015507000_CIT0023","doi-asserted-by":"publisher","first-page":"16091","DOI":"10.1074\/jbc.M110.193805","article-title":"The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem"},{"key":"2025031509015507000_CIT0024","first-page":"Abstract","article-title":"Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models","volume":"82","author":"Basu SR","year":"2022","journal-title":"Cancer Res"},{"key":"2025031509015507000_CIT0025","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025031509015507000_CIT0026","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025031509015507000_CIT0027","first-page":"2","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"2025031509015507000_CIT0028","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase i study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025031509015507000_CIT0029","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"2025031509015507000_CIT0030","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025031509015507000_CIT0031","doi-asserted-by":"publisher","first-page":"eaaz3577","DOI":"10.1126\/scitranslmed.aaz3577","article-title":"Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer","volume":"12","author":"Subudhi","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025031509015507000_CIT0032","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1200\/jco.2023.41.16_suppl.5057","article-title":"Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): a single-center prospective observational trial","volume":"41","author":"Zhu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025031509015507000_CIT0033","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae313\/61519143\/oyae313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae313\/61519143\/oyae313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:02:13Z","timestamp":1742029333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae313\/7964589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae313","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"oyae313"}}